U.S., July 19 -- ClinicalTrials.gov registry received information related to the study (NCT07072247) titled 'RN1201 Injection in the Treatment of Antibody-Mediated Diseases' on July 09.
Brief Summary: This single-arm, open-label exploratory trial aims to evaluate the safety, feasibility, and preliminary efficacy of RN1201 Injection in patients with antibody-mediated diseases, including refractory immune-mediated platelet transfusion refractoriness (PTR) and relapsed or refractory immune thrombocytopenia (ITP). Patients will receive RN1201 cells infusion following lymphodepletion. The study will assess safety, response rates, B-cell depletion, and immune reconstitution. Exploratory analyses will examine in vivo persistence and activity of R...